Role of Lysine‐Specific Demethylase 1 in Metabolically Integrating Osteoclast Differentiation and Inflammatory Bone Resorption Through Hypoxia‐Inducible Factor 1α and E2F1
Objective Hypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates inflammatory responses and increases bone resorption in inflammatory arthritis by enhancing osteoclastogenesis. The mechanism by which t...
Saved in:
Published in | Arthritis & rheumatology (Hoboken, N.J.) Vol. 74; no. 6; pp. 948 - 960 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Boston, USA
Wiley Periodicals, Inc
01.06.2022
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 2326-5191 2326-5205 2326-5205 |
DOI | 10.1002/art.42074 |
Cover
Abstract | Objective
Hypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates inflammatory responses and increases bone resorption in inflammatory arthritis by enhancing osteoclastogenesis. The mechanism by which the hypoxia response is linked to osteoclastogenesis and inflammatory bone resorption is unclear. This study was undertaken to evaluate whether the protein lysine‐specific demethylase 1 (LSD1) metabolically integrates inflammatory osteoclastogenesis and bone resorption in a state of inflammatory arthritis.
Methods
LSD1‐specific inhibitors and gene silencing with small interfering RNAs were used to inhibit the expression of LSD1 in human osteoclast precursor cells derived from CD14‐positive monocytes, with subsequent assessment by RNA‐sequencing analysis. In experimental mouse models of arthritis, inflammatory osteolysis, or osteoporosis, features of accelerated bone loss and inflammatory osteolysis were analyzed. Furthermore, in blood samples from patients with RA, cis‐acting expression quantitative trait loci (cis‐eQTL) were analyzed for association with the expression of hypoxia‐inducible factor 1α (HIF‐1α), and associations between HIF‐1α allelic variants and extent of bone erosion were evaluated.
Results
In human osteoclast precursor cells, RANKL induced the expression of LSD1 in a mechanistic target of rapamycin–dependent manner. Expression of LSD1 was higher in synovium from RA patients than in synovium from osteoarthritis patients. Inhibition of LSD1 in human osteoclast precursors suppressed osteoclast differentiation. Results of transcriptome analysis identified several LSD1‐mediated hypoxia and cell‐cycle pathways as key genetic pathways involved in human osteoclastogenesis. Furthermore, HIF‐1α protein, which is rapidly degraded by the proteasome in a normoxic environment, was found to be expressed in RANKL‐stimulated osteoclast precursor cells. Induction of LSD1 by RANKL stabilized the expression of HIF‐1α protein, thereby promoting glycolysis, in conjunction with up‐regulation of the transcription factor E2F1. Analyses of cis‐eQTL revealed that higher HIF‐1α expression was associated with increased bone erosion in patients with RA. Inhibition of LSD1 decreased pathologic bone resorption in mice, both in models of accelerated osteoporosis and models of arthritis and inflammatory osteolysis.
Conclusion
LSD1 metabolically regulates osteoclastogenesis in an energy‐demanding inflammatory environment. These findings provide potential new therapeutic strategies targeting osteoclasts in the management of inflammatory arthritis, including in patients with RA. |
---|---|
AbstractList | ObjectiveHypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates inflammatory responses and increases bone resorption in inflammatory arthritis by enhancing osteoclastogenesis. The mechanism by which the hypoxia response is linked to osteoclastogenesis and inflammatory bone resorption is unclear. This study was undertaken to evaluate whether the protein lysine‐specific demethylase 1 (LSD1) metabolically integrates inflammatory osteoclastogenesis and bone resorption in a state of inflammatory arthritis.MethodsLSD1‐specific inhibitors and gene silencing with small interfering RNAs were used to inhibit the expression of LSD1 in human osteoclast precursor cells derived from CD14‐positive monocytes, with subsequent assessment by RNA‐sequencing analysis. In experimental mouse models of arthritis, inflammatory osteolysis, or osteoporosis, features of accelerated bone loss and inflammatory osteolysis were analyzed. Furthermore, in blood samples from patients with RA, cis‐acting expression quantitative trait loci (cis‐eQTL) were analyzed for association with the expression of hypoxia‐inducible factor 1α (HIF‐1α), and associations between HIF‐1α allelic variants and extent of bone erosion were evaluated.ResultsIn human osteoclast precursor cells, RANKL induced the expression of LSD1 in a mechanistic target of rapamycin–dependent manner. Expression of LSD1 was higher in synovium from RA patients than in synovium from osteoarthritis patients. Inhibition of LSD1 in human osteoclast precursors suppressed osteoclast differentiation. Results of transcriptome analysis identified several LSD1‐mediated hypoxia and cell‐cycle pathways as key genetic pathways involved in human osteoclastogenesis. Furthermore, HIF‐1α protein, which is rapidly degraded by the proteasome in a normoxic environment, was found to be expressed in RANKL‐stimulated osteoclast precursor cells. Induction of LSD1 by RANKL stabilized the expression of HIF‐1α protein, thereby promoting glycolysis, in conjunction with up‐regulation of the transcription factor E2F1. Analyses of cis‐eQTL revealed that higher HIF‐1α expression was associated with increased bone erosion in patients with RA. Inhibition of LSD1 decreased pathologic bone resorption in mice, both in models of accelerated osteoporosis and models of arthritis and inflammatory osteolysis.ConclusionLSD1 metabolically regulates osteoclastogenesis in an energy‐demanding inflammatory environment. These findings provide potential new therapeutic strategies targeting osteoclasts in the management of inflammatory arthritis, including in patients with RA. Hypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates inflammatory responses and increases bone resorption in inflammatory arthritis by enhancing osteoclastogenesis. The mechanism by which the hypoxia response is linked to osteoclastogenesis and inflammatory bone resorption is unclear. This study was undertaken to evaluate whether the protein lysine-specific demethylase 1 (LSD1) metabolically integrates inflammatory osteoclastogenesis and bone resorption in a state of inflammatory arthritis.OBJECTIVEHypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates inflammatory responses and increases bone resorption in inflammatory arthritis by enhancing osteoclastogenesis. The mechanism by which the hypoxia response is linked to osteoclastogenesis and inflammatory bone resorption is unclear. This study was undertaken to evaluate whether the protein lysine-specific demethylase 1 (LSD1) metabolically integrates inflammatory osteoclastogenesis and bone resorption in a state of inflammatory arthritis.LSD1-specific inhibitors and gene silencing with small interfering RNAs were used to inhibit the expression of LSD1 in human osteoclast precursor cells derived from CD14-positive monocytes, with subsequent assessment by RNA-sequencing analysis. In experimental mouse models of arthritis, inflammatory osteolysis, or osteoporosis, features of accelerated bone loss and inflammatory osteolysis were analyzed. Furthermore, in blood samples from patients with RA, cis-acting expression quantitative trait loci (cis-eQTL) were analyzed for association with the expression of hypoxia-inducible factor 1α (HIF-1α), and associations between HIF-1α allelic variants and extent of bone erosion were evaluated.METHODSLSD1-specific inhibitors and gene silencing with small interfering RNAs were used to inhibit the expression of LSD1 in human osteoclast precursor cells derived from CD14-positive monocytes, with subsequent assessment by RNA-sequencing analysis. In experimental mouse models of arthritis, inflammatory osteolysis, or osteoporosis, features of accelerated bone loss and inflammatory osteolysis were analyzed. Furthermore, in blood samples from patients with RA, cis-acting expression quantitative trait loci (cis-eQTL) were analyzed for association with the expression of hypoxia-inducible factor 1α (HIF-1α), and associations between HIF-1α allelic variants and extent of bone erosion were evaluated.In human osteoclast precursor cells, RANKL induced the expression of LSD1 in a mechanistic target of rapamycin-dependent manner. Expression of LSD1 was higher in synovium from RA patients than in synovium from osteoarthritis patients. Inhibition of LSD1 in human osteoclast precursors suppressed osteoclast differentiation. Results of transcriptome analysis identified several LSD1-mediated hypoxia and cell-cycle pathways as key genetic pathways involved in human osteoclastogenesis. Furthermore, HIF-1α protein, which is rapidly degraded by the proteasome in a normoxic environment, was found to be expressed in RANKL-stimulated osteoclast precursor cells. Induction of LSD1 by RANKL stabilized the expression of HIF-1α protein, thereby promoting glycolysis, in conjunction with up-regulation of the transcription factor E2F1. Analyses of cis-eQTL revealed that higher HIF-1α expression was associated with increased bone erosion in patients with RA. Inhibition of LSD1 decreased pathologic bone resorption in mice, both in models of accelerated osteoporosis and models of arthritis and inflammatory osteolysis.RESULTSIn human osteoclast precursor cells, RANKL induced the expression of LSD1 in a mechanistic target of rapamycin-dependent manner. Expression of LSD1 was higher in synovium from RA patients than in synovium from osteoarthritis patients. Inhibition of LSD1 in human osteoclast precursors suppressed osteoclast differentiation. Results of transcriptome analysis identified several LSD1-mediated hypoxia and cell-cycle pathways as key genetic pathways involved in human osteoclastogenesis. Furthermore, HIF-1α protein, which is rapidly degraded by the proteasome in a normoxic environment, was found to be expressed in RANKL-stimulated osteoclast precursor cells. Induction of LSD1 by RANKL stabilized the expression of HIF-1α protein, thereby promoting glycolysis, in conjunction with up-regulation of the transcription factor E2F1. Analyses of cis-eQTL revealed that higher HIF-1α expression was associated with increased bone erosion in patients with RA. Inhibition of LSD1 decreased pathologic bone resorption in mice, both in models of accelerated osteoporosis and models of arthritis and inflammatory osteolysis.LSD1 metabolically regulates osteoclastogenesis in an energy-demanding inflammatory environment. These findings provide potential new therapeutic strategies targeting osteoclasts in the management of inflammatory arthritis, including in patients with RA.CONCLUSIONLSD1 metabolically regulates osteoclastogenesis in an energy-demanding inflammatory environment. These findings provide potential new therapeutic strategies targeting osteoclasts in the management of inflammatory arthritis, including in patients with RA. Objective Hypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates inflammatory responses and increases bone resorption in inflammatory arthritis by enhancing osteoclastogenesis. The mechanism by which the hypoxia response is linked to osteoclastogenesis and inflammatory bone resorption is unclear. This study was undertaken to evaluate whether the protein lysine‐specific demethylase 1 (LSD1) metabolically integrates inflammatory osteoclastogenesis and bone resorption in a state of inflammatory arthritis. Methods LSD1‐specific inhibitors and gene silencing with small interfering RNAs were used to inhibit the expression of LSD1 in human osteoclast precursor cells derived from CD14‐positive monocytes, with subsequent assessment by RNA‐sequencing analysis. In experimental mouse models of arthritis, inflammatory osteolysis, or osteoporosis, features of accelerated bone loss and inflammatory osteolysis were analyzed. Furthermore, in blood samples from patients with RA, cis‐acting expression quantitative trait loci (cis‐eQTL) were analyzed for association with the expression of hypoxia‐inducible factor 1α (HIF‐1α), and associations between HIF‐1α allelic variants and extent of bone erosion were evaluated. Results In human osteoclast precursor cells, RANKL induced the expression of LSD1 in a mechanistic target of rapamycin–dependent manner. Expression of LSD1 was higher in synovium from RA patients than in synovium from osteoarthritis patients. Inhibition of LSD1 in human osteoclast precursors suppressed osteoclast differentiation. Results of transcriptome analysis identified several LSD1‐mediated hypoxia and cell‐cycle pathways as key genetic pathways involved in human osteoclastogenesis. Furthermore, HIF‐1α protein, which is rapidly degraded by the proteasome in a normoxic environment, was found to be expressed in RANKL‐stimulated osteoclast precursor cells. Induction of LSD1 by RANKL stabilized the expression of HIF‐1α protein, thereby promoting glycolysis, in conjunction with up‐regulation of the transcription factor E2F1. Analyses of cis‐eQTL revealed that higher HIF‐1α expression was associated with increased bone erosion in patients with RA. Inhibition of LSD1 decreased pathologic bone resorption in mice, both in models of accelerated osteoporosis and models of arthritis and inflammatory osteolysis. Conclusion LSD1 metabolically regulates osteoclastogenesis in an energy‐demanding inflammatory environment. These findings provide potential new therapeutic strategies targeting osteoclasts in the management of inflammatory arthritis, including in patients with RA. Hypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates inflammatory responses and increases bone resorption in inflammatory arthritis by enhancing osteoclastogenesis. The mechanism by which the hypoxia response is linked to osteoclastogenesis and inflammatory bone resorption is unclear. This study was undertaken to evaluate whether the protein lysine-specific demethylase 1 (LSD1) metabolically integrates inflammatory osteoclastogenesis and bone resorption in a state of inflammatory arthritis. LSD1-specific inhibitors and gene silencing with small interfering RNAs were used to inhibit the expression of LSD1 in human osteoclast precursor cells derived from CD14-positive monocytes, with subsequent assessment by RNA-sequencing analysis. In experimental mouse models of arthritis, inflammatory osteolysis, or osteoporosis, features of accelerated bone loss and inflammatory osteolysis were analyzed. Furthermore, in blood samples from patients with RA, cis-acting expression quantitative trait loci (cis-eQTL) were analyzed for association with the expression of hypoxia-inducible factor 1α (HIF-1α), and associations between HIF-1α allelic variants and extent of bone erosion were evaluated. In human osteoclast precursor cells, RANKL induced the expression of LSD1 in a mechanistic target of rapamycin-dependent manner. Expression of LSD1 was higher in synovium from RA patients than in synovium from osteoarthritis patients. Inhibition of LSD1 in human osteoclast precursors suppressed osteoclast differentiation. Results of transcriptome analysis identified several LSD1-mediated hypoxia and cell-cycle pathways as key genetic pathways involved in human osteoclastogenesis. Furthermore, HIF-1α protein, which is rapidly degraded by the proteasome in a normoxic environment, was found to be expressed in RANKL-stimulated osteoclast precursor cells. Induction of LSD1 by RANKL stabilized the expression of HIF-1α protein, thereby promoting glycolysis, in conjunction with up-regulation of the transcription factor E2F1. Analyses of cis-eQTL revealed that higher HIF-1α expression was associated with increased bone erosion in patients with RA. Inhibition of LSD1 decreased pathologic bone resorption in mice, both in models of accelerated osteoporosis and models of arthritis and inflammatory osteolysis. LSD1 metabolically regulates osteoclastogenesis in an energy-demanding inflammatory environment. These findings provide potential new therapeutic strategies targeting osteoclasts in the management of inflammatory arthritis, including in patients with RA. |
Author | Ito, Hiromu Ito, Shuji Murata, Koichi Park‐Min, Kyung‐Hyun Ivashkiv, Lionel B. Tanaka, Masao Matsuda, Shuichi Terao, Chikashi Murotani, Yoshiki Umemoto, Akio Murakami, Kosaku Nishitani, Kohei Watanabe, Ryu Fujii, Takayuki Hashimoto, Motomu Ishie, Shinichiro Yoshitomi, Hiroyuki Doi, Kohei Suzuki, Akari Morinobu, Akio |
Author_xml | – sequence: 1 givenname: Kohei surname: Doi fullname: Doi, Kohei organization: Kyoto University Graduate School of Medicine – sequence: 2 givenname: Koichi orcidid: 0000-0002-7896-3937 surname: Murata fullname: Murata, Koichi email: kchm@kuhp.kyoto-u.ac.jp organization: Kyoto University Graduate School of Medicine, Kyoto, Japan, and Hospital for Special Surgery – sequence: 3 givenname: Shuji surname: Ito fullname: Ito, Shuji organization: RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, and Shimane University Faculty of Medicine – sequence: 4 givenname: Akari surname: Suzuki fullname: Suzuki, Akari organization: RIKEN Center for Integrative Medical Sciences – sequence: 5 givenname: Chikashi surname: Terao fullname: Terao, Chikashi organization: RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, and Shizuoka General Hospital and University of Shizuoka – sequence: 6 givenname: Shinichiro surname: Ishie fullname: Ishie, Shinichiro organization: Kyoto University Graduate School of Medicine – sequence: 7 givenname: Akio surname: Umemoto fullname: Umemoto, Akio organization: Kyoto University Graduate School of Medicine – sequence: 8 givenname: Yoshiki surname: Murotani fullname: Murotani, Yoshiki organization: Kyoto University Graduate School of Medicine – sequence: 9 givenname: Kohei surname: Nishitani fullname: Nishitani, Kohei organization: Kyoto University Graduate School of Medicine – sequence: 10 givenname: Hiroyuki surname: Yoshitomi fullname: Yoshitomi, Hiroyuki organization: Kyoto University Graduate School of Medicine – sequence: 11 givenname: Takayuki surname: Fujii fullname: Fujii, Takayuki organization: Kyoto University Graduate School of Medicine – sequence: 12 givenname: Ryu orcidid: 0000-0002-1089-5296 surname: Watanabe fullname: Watanabe, Ryu organization: Kyoto University Graduate School of Medicine – sequence: 13 givenname: Motomu surname: Hashimoto fullname: Hashimoto, Motomu organization: Kyoto University Graduate School of Medicine – sequence: 14 givenname: Kosaku surname: Murakami fullname: Murakami, Kosaku organization: Kyoto University Graduate School of Medicine – sequence: 15 givenname: Masao surname: Tanaka fullname: Tanaka, Masao organization: Kyoto University Graduate School of Medicine – sequence: 16 givenname: Hiromu orcidid: 0000-0002-1827-382X surname: Ito fullname: Ito, Hiromu organization: Kyoto University Graduate School of Medicine – sequence: 17 givenname: Kyung‐Hyun surname: Park‐Min fullname: Park‐Min, Kyung‐Hyun organization: Hospital for Special Surgery – sequence: 18 givenname: Lionel B. surname: Ivashkiv fullname: Ivashkiv, Lionel B. organization: Hospital for Special Surgery – sequence: 19 givenname: Akio surname: Morinobu fullname: Morinobu, Akio organization: Kyoto University Graduate School of Medicine – sequence: 20 givenname: Shuichi surname: Matsuda fullname: Matsuda, Shuichi organization: Kyoto University Graduate School of Medicine |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35077015$$D View this record in MEDLINE/PubMed |
BookMark | eNp90U1u1DAUB_AIFdFSuuACyBIbWEzrjzgfy34NHWlQpWFYR47zPOPKsYPtCLLjCBwFLsIhOAlmpmVRCbyxZf_e019-z7MD6yxk2UuCTwnG9Ez4eJpTXOZPsiPKaDHjFPODhzOpyWF2EsIdTqsucYH5s-yQcVyWmPCj7PvKGUBOoeUUtIVfX799GEBqpSW6gh7idjIiACJIW_Qeomid0VIYM6GFjbDxImq7QbchgpNJRnSllQIPNur05CwStktUGdH3Ijo_oYsUH60gOD_swHrr3bjZoptpcF-0SAkWthulblOuuZCpBpGfP3Z9rumcvMieKmECnNzvx9nH-fX68ma2vH23uDxfziSrqnzWdZwWslKtqqGFkghVsJyxTha1IqXMc55XWDHWyiKvOEjg6aKUHQdVl3kF7Dh7s-87ePdphBCbXgcJxggLbgwNLSgteE04S_T1I3rnRm9TuqRKwgmpC5zUq3s1tj10zeB1L_zUPMwigbd7IL0LwYP6Swhu_oy6SaNudqNO9uyRlTruPjx6oc3_Kj5rA9O_Wzfnq_W-4jcyqr4g |
CitedBy_id | crossref_primary_10_3389_fcimb_2025_1529692 crossref_primary_10_1186_s13075_023_03007_9 crossref_primary_10_1016_j_intimp_2022_109095 crossref_primary_10_1016_j_jphs_2023_09_005 crossref_primary_10_1002_advs_202403177 crossref_primary_10_1111_jcmm_70398 crossref_primary_10_1007_s10787_024_01552_6 crossref_primary_10_1002_jcp_30844 crossref_primary_10_1016_j_bioorg_2024_107603 crossref_primary_10_1016_j_heliyon_2024_e31314 crossref_primary_10_1016_j_bone_2024_117382 crossref_primary_10_1038_s41413_025_00413_4 crossref_primary_10_1038_s44324_024_00010_9 crossref_primary_10_1016_j_acthis_2023_152073 crossref_primary_10_3390_molecules29133191 crossref_primary_10_1080_08820139_2024_2337025 crossref_primary_10_1177_00368504241300723 crossref_primary_10_1177_09603271241269028 crossref_primary_10_3390_cells11223552 crossref_primary_10_1021_acschembio_3c00386 crossref_primary_10_3390_biomedicines12102292 crossref_primary_10_3390_md22020095 crossref_primary_10_1038_s41419_024_06521_z crossref_primary_10_3389_fimmu_2022_930244 crossref_primary_10_1016_j_intimp_2025_114017 crossref_primary_10_3389_fphys_2022_939253 crossref_primary_10_1016_j_biopha_2023_115646 crossref_primary_10_1016_j_freeradbiomed_2025_01_013 crossref_primary_10_1016_j_ijbiomac_2025_141807 crossref_primary_10_3892_ijmm_2022_5197 crossref_primary_10_1039_D3MA00733B crossref_primary_10_1016_j_gendis_2024_101307 crossref_primary_10_3390_ijms24043605 crossref_primary_10_1186_s12891_025_08274_y crossref_primary_10_1038_s42003_024_06581_z crossref_primary_10_1007_s11033_024_09353_4 crossref_primary_10_2147_IJN_S456533 crossref_primary_10_1093_jbmrpl_ziae142 crossref_primary_10_1016_j_apsb_2024_01_005 crossref_primary_10_1016_j_phrs_2024_107537 crossref_primary_10_3390_biom15010071 |
Cites_doi | 10.1136/annrheumdis-2018-214827 10.1038/nm.3815 10.1038/onc.2017.158 10.1111/imr.12841 10.1002/med.21350 10.1038/nature06905 10.1158/1535-7163.MCT-18-0373 10.1016/j.biocel.2016.08.034 10.1007/s00774-006-0725-9 10.1038/nrrheum.2017.213 10.1182/blood-2012-01-405993 10.1016/j.immuni.2017.06.018 10.1002/jcp.22798 10.1186/s12881-019-0767-1 10.1021/jm400870h 10.1002/jbmr.1976 10.1038/s41413-018-0015-x 10.1038/s41577-019-0178-8 10.1186/s13045-019-0811-9 10.1016/j.immuni.2014.09.008 10.1007/s00018-020-03489-9 10.1016/j.bbagrm.2019.03.004 10.1038/nm.3774 10.1016/j.biocel.2004.08.012 10.1084/jem.20112607 10.1172/JCI93356 10.1038/ng.3885 10.1172/JCI89935 10.1002/art.40504 10.1038/ncomms10347 10.1056/NEJMcp1513724 10.1016/j.jmb.2016.10.004 10.1007/s00281-019-00757-0 10.1038/leu.2014.119 10.1111/cas.13990 10.1038/s42255-020-00318-y 10.1172/JCI26132 10.1016/j.cmet.2014.07.011 |
ContentType | Journal Article |
Copyright | 2022 American College of Rheumatology 2022 American College of Rheumatology. |
Copyright_xml | – notice: 2022 American College of Rheumatology – notice: 2022 American College of Rheumatology. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7T5 7TM 7U7 C1K H94 K9. 7X8 |
DOI | 10.1002/art.42074 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Toxicology Abstracts Bacteriology Abstracts (Microbiology B) Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Toxicology Abstracts MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2326-5205 |
EndPage | 960 |
ExternalDocumentID | 35077015 10_1002_art_42074 ART42074 |
Genre | article Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: Japan Society for the Promotion of Science funderid: 17H06816; 18H02926 – fundername: Inamori Foundation – fundername: Kanae Foundation for the Promotion of Medical Science – fundername: National Institute of Arthritis and Musculoskeletal and Skin Diseases funderid: DE019420 – fundername: Takeda Science Foundation – fundername: NIDCR NIH HHS grantid: R01 DE019420 – fundername: NIAMS NIH HHS grantid: DE019420 |
GroupedDBID | 0R~ 1OC 24P 33P 3SF 4.4 52O 52U 52V 53G 5VS AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAQQT AASGY AAWTL AAXRX AAYCA AAZKR ABCUV ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZFZN AZVAB BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 DCZOG DIK DRFUL DRMAN DRSTM EBS EJD EMOBN EX3 F00 FUBAC G-S G.N GODZA HGLYW KBYEO LATKE LEEKS LH4 LITHE LOXES LUTES LW6 LYRES MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM NF~ O66 O9- OK1 OVD P2W PQQKQ QB0 ROL SUPJJ SV3 TEORI V9Y WBKPD WHWMO WIH WIJ WIK WOHZO WVDHM WXSBR YCJ AAFWJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7QL 7QP 7T5 7TM 7U7 C1K H94 K9. 7X8 |
ID | FETCH-LOGICAL-c3884-dd526c8fbf9ebe71af63433dc69f17c445480f33bc6485ece55487cd5ef9748e3 |
ISSN | 2326-5191 2326-5205 |
IngestDate | Fri Jul 11 08:38:59 EDT 2025 Fri Jul 25 12:29:17 EDT 2025 Mon Jul 21 05:44:24 EDT 2025 Tue Jul 01 00:56:05 EDT 2025 Thu Apr 24 22:54:59 EDT 2025 Wed Jan 22 16:26:09 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
License | 2022 American College of Rheumatology. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3884-dd526c8fbf9ebe71af63433dc69f17c445480f33bc6485ece55487cd5ef9748e3 |
Notes | Dr. Murata's work was supported by the KANAE Foundation for the Promotion of Medical Science, Takeda Science Foundation, Inamori Foundation, and JSPS KAKENHI (grants 17H06816 and 18H02926). Research conducted in the US at the Hospital for Special Surgery was supported by the NIH (grant DE‐019420). . Author disclosures are available at https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fart.42074&file=art42074‐sup‐0001‐Disclosureform.pdf ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-7896-3937 0000-0002-1089-5296 0000-0002-1827-382X |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/9156537 |
PMID | 35077015 |
PQID | 2671511960 |
PQPubID | 946334 |
PageCount | 13 |
ParticipantIDs | proquest_miscellaneous_2622659153 proquest_journals_2671511960 pubmed_primary_35077015 crossref_primary_10_1002_art_42074 crossref_citationtrail_10_1002_art_42074 wiley_primary_10_1002_art_42074_ART42074 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | June 2022 2022-06-00 20220601 |
PublicationDateYYYYMMDD | 2022-06-01 |
PublicationDate_xml | – month: 06 year: 2022 text: June 2022 |
PublicationDecade | 2020 |
PublicationPlace | Boston, USA |
PublicationPlace_xml | – name: Boston, USA – name: United States – name: Atlanta |
PublicationTitle | Arthritis & rheumatology (Hoboken, N.J.) |
PublicationTitleAlternate | Arthritis Rheumatol |
PublicationYear | 2022 |
Publisher | Wiley Periodicals, Inc Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Periodicals, Inc – name: Wiley Subscription Services, Inc |
References | 2015; 35 2012; 120 2013; 28 2017; 47 2017; 49 2019; 78 2005; 115 2019; 12 2019; 19 2020; 77 2014; 28 2014; 41 2012; 227 2016; 79 2014; 20 2019; 1862 2012; 209 2018; 6 2017; 429 2016; 7 2018; 17 2020; 2 2019; 20 2019; 41 2017; 36 2020; 294 2013; 56 2015; 21 2018; 70 2020; 26 2016; 374 2005; 37 2008; 453 2018; 11 2017; 127 2007; 25 2018; 14 2019; 110 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_22_1 e_1_2_8_23_1 Liu W (e_1_2_8_39_1) 2018; 11 e_1_2_8_41_1 e_1_2_8_40_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_16_1 e_1_2_8_37_1 Tsourdi E (e_1_2_8_6_1) 2020; 26 e_1_2_8_32_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_30_1 |
References_xml | – volume: 56 start-page: 9496 year: 2013 end-page: 508 article-title: High‐throughput virtual screening identifies novel N’‐(1‐phenylethylidene)‐benzohydrazides as potent, specific, and reversible LSD1 inhibitors publication-title: J Med Chem – volume: 28 start-page: 2392 year: 2013 end-page: 9 article-title: Metabolic regulation of osteoclast differentiation and function publication-title: J Bone Miner Res – volume: 21 start-page: 281 year: 2015 end-page: 7 article-title: DNA methyltransferase 3a regulates osteoclast differentiation by coupling to an S‐adenosylmethionine‐producing metabolic pathway publication-title: Nat Med – volume: 26 year: 2020 article-title: Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS publication-title: J Clin Endocrinol Metab – volume: 49 start-page: 1120 year: 2017 end-page: 5 article-title: Polygenic burdens on cell‐specific pathways underlie the risk of rheumatoid arthritis publication-title: Nat Genet – volume: 127 start-page: 2030 year: 2017 end-page: 9 article-title: Inflammatory osteolysis: a conspiracy against bone publication-title: J Clin Invest – volume: 12 start-page: 129 year: 2019 article-title: LSD1/KDM1A inhibitors in clinical trials: advances and prospects publication-title: J Hematol Oncol – volume: 6 start-page: 14 year: 2018 article-title: Histone demethylase LSD1 regulates bone mass by controlling WNT7B and BMP2 signaling in osteoblasts publication-title: Bone Res – volume: 70 start-page: 984 year: 2018 end-page: 99 article-title: Synovial cell metabolism and chronic inflammation in rheumatoid arthritis [review] publication-title: Arthritis Rheumatol – volume: 110 start-page: 1510 year: 2019 end-page: 7 article-title: Hypoxia/pseudohypoxia‐mediated activation of hypoxia‐inducible factor‐1α in cancer [review] publication-title: Cancer Sci – volume: 227 start-page: 514 year: 2012 end-page: 24 article-title: Functional regulation of HIF‐1α under normoxia—is there more than post‐translational regulation? publication-title: J Cell Physiol – volume: 41 start-page: 565 year: 2019 end-page: 72 article-title: Metabolic reprogramming in osteoclasts publication-title: Semin Immunopathol – volume: 115 start-page: 3418 year: 2005 end-page: 27 article-title: M‐CSF mediates TNF‐induced inflammatory osteolysis publication-title: J Clin Invest – volume: 120 start-page: 3118 year: 2012 end-page: 25 article-title: Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia‐inducible factor 1 α publication-title: Blood – volume: 209 start-page: 2441 year: 2012 end-page: 53 article-title: PDK1 regulation of mTOR and hypoxia‐inducible factor 1 integrate metabolism and migration of CD8+ T cells publication-title: J Exp Med – volume: 77 start-page: 3341 year: 2020 end-page: 50 article-title: Biological roles of LSD1 beyond its demethylase activity publication-title: Cell Mol Life Sci – volume: 453 start-page: 807 year: 2008 end-page: 11 article-title: NF‐κB links innate immunity to the hypoxic response through transcriptional regulation of HIF‐1α publication-title: Nature – volume: 1862 start-page: 535 year: 2019 end-page: 46 article-title: Inhibition of lysine‐specific demethylase LSD1 induces senescence in glioblastoma cells through a HIF‐1alpha‐dependent pathway publication-title: Biochim Biophys Acta Gene Regul Mech – volume: 374 start-page: 254 year: 2016 end-page: 62 article-title: Clinical practice: postmenopausal osteoporosis publication-title: N Engl J Med – volume: 78 start-page: 899 year: 2019 end-page: 907 article-title: Effects of the anti‐RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease‐modifying antirheumatic drugs (DESIRABLE study): a randomised, double‐blind, placebo‐controlled phase 3 trial publication-title: Ann Rheum Dis – volume: 2 start-page: 1382 year: 2020 end-page: 90 article-title: Stepwise cell fate decision pathways during osteoclastogenesis at single‐cell resolution publication-title: Nat Metab – volume: 28 start-page: 2155 year: 2014 end-page: 64 article-title: Highly effective combination of LSD1 (KDM1A) antagonist and pan‐histone deacetylase inhibitor against human AML cells publication-title: Leukemia – volume: 20 start-page: 483 year: 2014 end-page: 98 article-title: Mitochondrial complex I activity suppresses inflammation and enhances bone resorption by shifting macrophage‐osteoclast polarization publication-title: Cell Metab – volume: 11 start-page: 333 year: 2018 end-page: 41 article-title: Knockdown of LSD1 ameliorates the severity of rheumatoid arthritis and decreases the function of CD4 T cells in mouse models publication-title: Int J Clin Exp Pathol – volume: 21 start-page: 212 year: 2015 end-page: 3 article-title: Metabolic‐epigenetic coupling in osteoclast differentiation publication-title: Nat Med – volume: 37 start-page: 535 year: 2005 end-page: 40 article-title: Hypoxia‐inducible factor 1: regulation by hypoxic and non‐hypoxic activators publication-title: Int J Biochem Cell Biol – volume: 41 start-page: 518 year: 2014 end-page: 28 article-title: HIF transcription factors, inflammation, and immunity publication-title: Immunity – volume: 7 start-page: 10347 year: 2016 article-title: Methylation‐dependent regulation of HIF‐1α stability restricts retinal and tumour angiogenesis publication-title: Nat Commun – volume: 17 start-page: 1902 year: 2018 end-page: 16 article-title: Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma with SP‐2509 engages the endoplasmic reticulum stress response publication-title: Mol Cancer Ther – volume: 294 start-page: 164 year: 2020 end-page: 76 article-title: Impaired T cell receptor signaling and development of T cell‐mediated autoimmune arthritis [review] publication-title: Immunol Rev – volume: 19 start-page: 626 year: 2019 end-page: 42 article-title: Osteoimmunology: evolving concepts in bone‐immune interactions in health and disease [review] publication-title: Nat Rev Immunol – volume: 14 start-page: 146 year: 2018 end-page: 56 article-title: Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity [review] publication-title: Nat Revi Rheumatol – volume: 35 start-page: 1032 year: 2015 end-page: 71 article-title: A systematic review of histone lysine‐specific demethylase 1 and its inhibitors publication-title: Med Res Rev – volume: 429 start-page: 2055 year: 2017 end-page: 65 article-title: Systematic analysis of known and candidate lysine demethylases in the regulation of myoblast differentiation publication-title: J Mol Biol – volume: 20 start-page: 37 year: 2019 article-title: HIF‐1 transcription activity: HIF1A driven response in normoxia and in hypoxia publication-title: BMC Med Genet – volume: 127 start-page: 2555 year: 2017 end-page: 68 article-title: MYC‐dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor ERRα publication-title: J Clin Invest – volume: 47 start-page: 66 year: 2017 end-page: 79 article-title: Hypoxia‐sensitive COMMD1 integrates signaling and cellular metabolism in human macrophages and suppresses osteoclastogenesis publication-title: Immunity – volume: 25 start-page: 36 year: 2007 end-page: 45 article-title: Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood publication-title: J Bone Miner Metab – volume: 79 start-page: 168 year: 2016 end-page: 80 article-title: Energy metabolism in osteoclast formation and activity publication-title: Int J Biochem Cell Biol – volume: 36 start-page: 5512 year: 2017 end-page: 21 article-title: LSD1 demethylates HIF1α to inhibit hydroxylation and ubiquitin‐mediated degradation in tumor angiogenesis publication-title: Oncogene – ident: e_1_2_8_5_1 doi: 10.1136/annrheumdis-2018-214827 – ident: e_1_2_8_14_1 doi: 10.1038/nm.3815 – ident: e_1_2_8_20_1 doi: 10.1038/onc.2017.158 – ident: e_1_2_8_23_1 doi: 10.1111/imr.12841 – ident: e_1_2_8_33_1 doi: 10.1002/med.21350 – ident: e_1_2_8_27_1 doi: 10.1038/nature06905 – ident: e_1_2_8_41_1 doi: 10.1158/1535-7163.MCT-18-0373 – ident: e_1_2_8_10_1 doi: 10.1016/j.biocel.2016.08.034 – ident: e_1_2_8_19_1 doi: 10.1007/s00774-006-0725-9 – ident: e_1_2_8_3_1 doi: 10.1038/nrrheum.2017.213 – ident: e_1_2_8_25_1 doi: 10.1182/blood-2012-01-405993 – ident: e_1_2_8_15_1 doi: 10.1016/j.immuni.2017.06.018 – ident: e_1_2_8_29_1 doi: 10.1002/jcp.22798 – ident: e_1_2_8_30_1 doi: 10.1186/s12881-019-0767-1 – ident: e_1_2_8_40_1 doi: 10.1021/jm400870h – ident: e_1_2_8_12_1 doi: 10.1002/jbmr.1976 – ident: e_1_2_8_37_1 doi: 10.1038/s41413-018-0015-x – ident: e_1_2_8_7_1 doi: 10.1038/s41577-019-0178-8 – ident: e_1_2_8_34_1 doi: 10.1186/s13045-019-0811-9 – ident: e_1_2_8_16_1 doi: 10.1016/j.immuni.2014.09.008 – ident: e_1_2_8_17_1 doi: 10.1007/s00018-020-03489-9 – ident: e_1_2_8_21_1 doi: 10.1016/j.bbagrm.2019.03.004 – ident: e_1_2_8_9_1 doi: 10.1038/nm.3774 – ident: e_1_2_8_24_1 doi: 10.1016/j.biocel.2004.08.012 – ident: e_1_2_8_26_1 doi: 10.1084/jem.20112607 – ident: e_1_2_8_2_1 doi: 10.1172/JCI93356 – ident: e_1_2_8_22_1 doi: 10.1038/ng.3885 – ident: e_1_2_8_8_1 doi: 10.1172/JCI89935 – ident: e_1_2_8_38_1 doi: 10.1002/art.40504 – ident: e_1_2_8_32_1 doi: 10.1038/ncomms10347 – ident: e_1_2_8_4_1 doi: 10.1056/NEJMcp1513724 – ident: e_1_2_8_36_1 doi: 10.1016/j.jmb.2016.10.004 – ident: e_1_2_8_13_1 doi: 10.1007/s00281-019-00757-0 – ident: e_1_2_8_35_1 doi: 10.1038/leu.2014.119 – ident: e_1_2_8_28_1 doi: 10.1111/cas.13990 – ident: e_1_2_8_31_1 doi: 10.1038/s42255-020-00318-y – volume: 11 start-page: 333 year: 2018 ident: e_1_2_8_39_1 article-title: Knockdown of LSD1 ameliorates the severity of rheumatoid arthritis and decreases the function of CD4 T cells in mouse models publication-title: Int J Clin Exp Pathol – ident: e_1_2_8_18_1 doi: 10.1172/JCI26132 – ident: e_1_2_8_11_1 doi: 10.1016/j.cmet.2014.07.011 – volume: 26 start-page: dgaaa756 year: 2020 ident: e_1_2_8_6_1 article-title: Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS publication-title: J Clin Endocrinol Metab |
SSID | ssj0000970605 |
Score | 2.5612166 |
Snippet | Objective
Hypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It... Hypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates... ObjectiveHypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 948 |
SubjectTerms | Animal models Animals Arthritis Arthritis, Rheumatoid Biomedical materials Bone loss Bone resorption Bone Resorption - metabolism Bone Resorption - pathology CD14 antigen Cell Differentiation Cell Hypoxia Differentiation E2F1 Transcription Factor - metabolism Evaluation Gene mapping Gene regulation Gene sequencing Gene silencing Glycolysis Histone Demethylases - genetics Histone Demethylases - metabolism Humans Hypoxia Hypoxia-Inducible Factor 1, alpha Subunit - metabolism Inflammation Joint diseases Lysine Mice Monocytes Osteoarthritis Osteoclastogenesis Osteoclasts Osteoclasts - metabolism Osteoclasts - pathology Osteolysis Osteolysis - metabolism Osteolysis - pathology Osteoporosis Osteoporosis - metabolism Osteoporosis - pathology Osteoprogenitor cells Precursors Proteasomes Proteins Quantitative trait loci RANK Ligand - metabolism Rapamycin Rheumatoid arthritis Synovium TOR protein TRANCE protein Tumors |
Title | Role of Lysine‐Specific Demethylase 1 in Metabolically Integrating Osteoclast Differentiation and Inflammatory Bone Resorption Through Hypoxia‐Inducible Factor 1α and E2F1 |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fart.42074 https://www.ncbi.nlm.nih.gov/pubmed/35077015 https://www.proquest.com/docview/2671511960 https://www.proquest.com/docview/2622659153 |
Volume | 74 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2326-5205 dateEnd: 20240929 omitProxy: true ssIdentifier: ssj0000970605 issn: 2326-5191 databaseCode: DIK dateStart: 19990101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtpAEF3RVKr6UvVe2rTaVkWqhExZr6-PJIBIAonUgMSbZS9r4YZiSm2p5Jv60h_JN3X2gjGBSmlfLGtZvJbOYZiZnZ2D0EduxZy7JDZoaEaGRd3IiAB2Y2K5E86IyahMuA3Ond7IOh3b40rlplS1lGdRg13vPVfyP6jCGOAqTsn-A7LFQ2EA7gFfuALCcL0Txl90aWB_JarXDaklHycMjIgQhl6BY8zrRGQ0BjwDsEV-bjZbySygaBEhsgQXgHLKYGYG1k9ppWQKLV0pHANlvqmt-KN0zmW-f6nszFBr_PRWi_RnEhpCBoQl4ihWV6r41EntuFM7IvJJHYjdy55wa5lNZUMlSb7llOdiFdkQCpzeXhqlV1yfBTttlPIV7VTVH6RTnpTYEiov-CxN2LQYP5EaUfXLaf61GLvMr3Ml1d26CpdJOesBAXNRnaWMIziCDgTRTbUjzveMaeuuNIA0i8um2lcdPnf-QlRLWsC0YZlN_e2tNt3nF0F31O8Hw854WKPdxXdDaJiJvf4abSuS3UP3TddxhKJG--SsyPk1fdGryJZ6h_pV182umubnYsltF2kn7tkOo6QfNHyMHukABrcUG5-gCp8_RQ8GukTjGfolSInTGN8iJS6REhOczPEWKXGJlHhDSnyLlBiohMukxIKUeENKrEmJd0iJFSkxufktnyII-RyNup3hcc_QkiAGo54HJmRimw7z4ij2wfq4JIwdalE6YY4fE5dZlmhfGFMaMcfybM64LSJyNrF5DIGzx-kLdDCH93qFMIk8CKVD8OfBQ3VD5vmx7_kmsynnJqFeFX1aoxAw3S9fyLbMAtXp2wwAsEACVkUfiqkL1SRm36TDNZSBtiE_AtNxidjJd5pV9L74GCy82LYL5zzNxRwIkWwfXJMqeqkoUKxCIZxzwaOHl5Wc-PvyAcTH8ub1HRZ6gx5ufnSH6CBb5vwtON9Z9E4y-g-mKt6G |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+Lysine-Specific+Demethylase+1+in+Metabolically+Integrating+Osteoclast+Differentiation+and+Inflammatory+Bone+Resorption+Through+Hypoxia-Inducible+Factor+1%CE%B1+and+E2F1&rft.jtitle=Arthritis+%26+rheumatology+%28Hoboken%2C+N.J.%29&rft.au=Doi%2C+Kohei&rft.au=Murata%2C+Koichi&rft.au=Ito%2C+Shuji&rft.au=Suzuki%2C+Akari&rft.date=2022-06-01&rft.issn=2326-5205&rft.eissn=2326-5205&rft.volume=74&rft.issue=6&rft.spage=948&rft_id=info:doi/10.1002%2Fart.42074&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2326-5191&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2326-5191&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2326-5191&client=summon |